2021 年実績
論文（英文）
1. Wada H, Ichikawa Y, Ezaki M, Shiraki K, Moritani I, Yamashita Y, Matsumoto T,Masuya M, Tawara I, Shimpo H, Shimaoka M.
Clot Waveform Analysis Demonstrates Low Blood Coagulation Ability in Patients with
Idiopathic Thrombocytopenic Purpura. J Clin Med. 2021 Dec 20;10: 5987
2. Kobayashi M, Wada H, Fukui S, Mizutani H, Ichikawa Y, Shiraki K, Moritani I, Inoue H,Shimaoka M, Shimpo H.
A Clot Waveform Analysis Showing a Hypercoagulable State in Patients with MalignantNeoplasms. J Clin Med. 2021; 10: 5352.
3. Seki Y, Honda G, Kawano N, Uchiyama T, Kawasugi K, Madoiwa S, Takezako N, IkezoeT, Wada H.
Clinical features of DIC according to the French – American - British (FAB)
classification in patients with acute leukemia and thrombomodulin alfa treatment – A
cohort study using a post-marketing surveillance database –. Clin Appl ThrombHemost. 2021 Jan-Dec; 27:10760296211054094.
4. Wada H, Ichikawa Y, Ezaki E, Matsumoto T, Yamashita Y, Shiraki K, Shimaoka M,Shimpo H.
The reevaluation of thrombin time using a clot waveform analysis. J. Clin. Med. 2021,10, 4840.
5. Yamamoto A, Wada H, Ichikawa Y, Mizuno H, Tomida M, Masuda J, Makino K,Kodama S, Yoshida M, Fukui S, Moritani I, Inoue H, Shiraki K, Shimpo H.
Evaluation of Biomarkers of Severity in Patients with COVID-19 Infection. J Clin Med.
2021; 10: 3775.
6. Hayashi K, Wada H, Shiraki K, Makino K.
Immune Thrombocytopenia and Cerebral Hemorrhaging Associated with COVID-19.
Intern Med. 2021; 60: 3513.
7. Nishigaki A, Ichikawa Y, Ezaki E, Yamamoto A, Suzuki K, Tachibana K, Kamon T, HorieS, Masuda J, Makino K, Shiraki K, Shimpo H, Shimaoka M, Suzuki-Inoue K, Wada H.
Soluble C-type lectin-like receptor 2 elevation in patients with acute cerebral infarction.
J Clin Med. 2021; 10: 3408.
8. Madoiwa S, Honda G, Kawano N, Uchiyama T, Kawasugi K, Takezako N, Suzuki K, SekiY, Ikezoe T, Okamoto K, Wada H.
An evaluation of the Japanese Society on Thrombosis and Hemostasis criteria fordisseminated intravascular coagulation as a predictor of prognosis in patients withinfection. Int J Lab Hematol. 2021; 43: 1566-74.
9. Yamamoto A, Wada H, Ichkawa Y, Tanaka M, Tashiro H, Shiraki K, Shimpo H,

Yamashita Y, Mastumoto T, Shimaoka M, Iba T, Suzuki-Inoue K.
Soluble C-Type Lectin-Like Receptor 2 Is a Biomarker for Disseminated IntravascularCoagulation. J Clin Med. 2021 Jun 28;10: 2860.
10. Habe K, Wada H, Mizutani K, Matsushima Y, Kondo M, Yamanaka K.
The clinical significance of a shortened activated partial thromboplastin time in patientswith connective tissue disease. Clin Rheumatol. 2021 Jun 16.
11. Hasegawa M, Tone S, Wada H, Naito Y, Matsumoto T, Yamashita Y, Shimaoka M, SudoA.
The evaluation of hemostatic abnormalities using a CWA-small amount tissue factor
induced FIX activation assay in major orthopedic surgery patients. Clin Appl Thromb
Hemost. 2021 Jan-Dec; 27: 1076029620976913.
12. Maeda K, Wada H, Shinkai T, Tanemura A, Matsumoto T, Mizuno S.
Evaluation of hemostatic abnormalities in patients who underwent major hepatobiliary
pancreatic surgery using activated partial thromboplastin time-clot waveform analysis.
Thromb Res. 2021; 201:154-160.
13. Kawasugi K, Wada H, Honda G, Kawano N, Uchiyama T, Madoiwa S, Takezako N,Suzuki K, Seki Y, Ikezoe T, Iba T, Okamoto K.
Hypofibrinogenemia is associated with a high degree of risk in infectious diseases: apost-hoc analysis of post-marketing surveillance of patients with disseminatedintravascular coagulation treated with thrombomodulin alfa. Thromb J. 2021; 19: 12.
14. Wada H, Shiraki K, Matsumoto T, Ohishi K, Shimpo H, Sakano Y, Nishii H, Shimaoka
M.
The Evaluation of APTT Reagents in Reference Plasma, Recombinant FVIII Products;
Kovaltry® and Jivi® Using CWA, Including sTF/7FIX Assay. Clin Appl Thromb Hemost.
2021 Jan-Dec;27
15. Sakai K, Wada H, Nakatsuka Y, Kubo M, Hayakawa M, Matsumoto M.
Characteristics Behaviors of Coagulation and Fibrinolysis Markers in Acquired
Thrombotic Thrombocytopenic Purpura. J Intensive Care Med. 2021; 36: 436-442
16. Iba T, Umemura Y, Wada H, Levy H.
The Roles of Coagulation Disorder and Microthrombosis in Sepsis: Pathophysiology,Diagnosis, and Treatment. Arch Med Res. 2021: 52: 788-797.
17. Wada H, Ichinose A, Katsuya Shiraki K, Shimpo H, Shimaoka M.
Coagulation factor V inhibitors, a review of the case report literature. Thrombosis
Update 2021; 4 100058
18. Iba T, Connors JM, Spyropoulos AC, Wada H, Levy JH.
Ethnic differences in thromboprophylaxis for COVID-19 patients: should they beconsidered. Int J Hematol. 2021; 113: 330-6

論文（和文）1. 和田英夫、宮村優里：二次性 TMA、Thrombosis Medicine、2021; 11: 56-60
2. 和田英夫、池田望 : 自己免疫性凝固第 V/5 因子欠乏症、Thrombosis Medicine、2021;
11: 292
3. 和田英夫、田中素子、江崎実：抗凝固薬・抗血小板薬投与患者、周術期の薬の使い方
パーフェクトガイド、月間薬事、丸山一男編、じほう、pp177-182、2021
4. 和田英夫： 血栓性微小血管症、診療ガイドライン UP-TO-DADE 2020-2021, 門脇孝、小室一成、宮地良樹 監修、メディカルレビュー社、大阪市、2021 年、pp513-517
5. 和田英夫、池田望：播種性血管内凝固（DIC）、159-163、一般社団法人内科系学会社
会保険連合編、医学書院、2021

学会発表
国際学会
シンポジウム1. Wada H: Update on the management of DIC. Symposium: Janus Diseases with
Thrombosis and Bleeding. Virtual Congress of the XIth APSTH 2021 (Korea,Gwangju), 2021, March 18-20
国内学会
シンポジウム1. 和田英夫: Small amount tissue factor induced FIX activation (sTF/FIXa)assay、第 15回日本血栓止血学会 SSC シンポジウム、2021、2 月 27 日（東京）Video 発表
2. 和田英夫、本田剛一、河野 徳明、内山俊正、川杉和夫、窓岩清治、竹迫直樹、鈴木圭、関 義信、池添隆之、岡本好司、射場敏明：後天性の著明アンチトロンビン低下
は、線溶抑制を伴い、ＤＩＣの予後を著しく悪くする。―リコモジュリン市販後調査
成績の解析―第 15 回日本血栓止血学会 SSC シンポジウム、2021、2 月 27 日（東京）Video 発表